01灵麦药业聚焦点全世界及我国的孤儿药界定全世界及我国的多发性硬化症的患病率及医治进度多发性硬化症全世界销售量龙虎榜及与我国市场销售之较为全世界与我国多发性硬化症医治手册的较为全世界与我国多发性硬化症新发展趋势动态性总览多发性硬化症最新项目共享Orphan drug definition globally and ChinaEpidemiology and treatment of Multiple Sclerosis (MS) globally and in ChinaMS indication Global top sales product and pipeline compare to ChinaGlobal treatment guideline v.s. ChinaGlobal and China MS innovation at a glanceLingmed Asset Recommendation02特惠活动时间: 2019年9月19日星期四 4:00 PM - 5:00PM地址: Webex演说: 曹莹莹,CEO & 灵麦药业创办人; 王海盛,医药学咨询顾问报考：021-5386 3003RSVP：此次专题讲座免費(优先选择灵麦药业目前VIP顾客) 请在2019年9月18此前申请注册DATE: Thursday September 19, 2019 4:00 PM - 5:00 PMVENUE: Webex PRESENTERS：Lingling Cao, CEO & Founder ，Dr. Hank Wang, Medical advisorREGISTER ：+86 21 5386 3003RSVP：This is a FREE event VIP tickets priority for Lingmed current clients. Please RSVP by September 18, 201903主题活动日程表16 : 00-16 : 10 灵佰服务项目及项目概况-曹莹莹 讲学16 : 10-16 : 45 我国孤儿药的产品研发最新政策下的销售市场项目投资机遇－多发性硬化症是罕见病吗？-王海盛博士研究生 讲学16 : 45-16 : 55 提出问题和探讨16 : 55-17 : 00 总结及意见反馈16 : 00-16 : 10 Linkedbio services & projects introductions-by LingLing Cao 16 : 10-16 : 45 Orphan drug? Another Breakthrough for “MS" - Global and China analysis. Are you ready? - by Dr. Hank Wan16 : 45-16 : 55 Panel discussions16 : 55-17 : 00 Q&A04参加特邀嘉宾曹莹莹 CEO & 创办人曹女士大学毕业于上海第二医科大学现交大医科院的临床医学专业系。并在欧州西班牙马斯特里斯特高校获得国际金融的研究生学位。她曾认职法国麦肯锡顾问很多年，致力于医疗行业。她也曾在几间大中型医药外企企业认职，如葛兰素史克，拜耳等。过去两年中，曹女士曾在礼来制药出任药物业务流程扩展部的高級主管及集博企业的国际商务主管岗位Lingling Cao CEO & FounderLingling has more than a decade of experience in the healthcare industry, especially in deal-making. She founded Lingmed, which aims to support BD professionals to make better decisions with intelligence databases and EU-China cross-border deals. Prior to her venture at Lingmed, she was a senior BD manager for Eli Lilly in Shanghai and a consultant for McKinsey in Germany王海盛 医药学咨询顾问王博士研究生在北大药物化学获得博士研究生，并依次在密苏里大学圣路易斯校区及奥本大学从业过博士研究生科学研究工作中。王海盛有着10年左右的医疗行业的从事工作经验，现阶段担任英国药理学生物学家研究会我国qq讨论组（AAPSCDG）现任主席；北大药学院做兼职专家教授、专硕老师；中国药业生物科技研究会(CMBA)生物医学信息科技联合会委员会；王博士研究生是灵麦精英团队引入自主创新药物层面的技术专业顾Dr. Hank Wang Medical advisorDr Wang holds a PhD degree on Medicinal Chemistry from Peking University, has a Postdoc experience in University of Missouri-Saint Louis, and worked as a Postdoc Fellow in Auburn University. Hank Wang has more than 10 years’ experience in pharmaceuticals industry. Hank has worked as Vice President and President of R&D at Beijing Haiyan Pharmaceutical Co., Ltd. - Yangtze River Pharmaceutical Group. Dr Wang advises Lingmed on innovative assets evaluation for China market请点一下文尾“阅读” 立刻申请注册吧或在线留言info@lingmed.net灵麦药业是下列俩家谍报数据库查询在我国的独家代理合作方：Biotechgate/博谷 - 全世界自主创新药和器材商品回收和引入数据库查询EvaluatePharma/预计药业 - 全世界药业产品研发、市场销售、销售市场预计等竞争情报数据库查询或点一下正下方“阅读”立刻申请注册吧灵麦免费在线webinar-我国孤儿药的产品研发最新政策下的销售市场项目投资机遇-多发性硬化症是罕见病吗? 2019.9.19 4PM-5PM
